Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30. November 2020 16:15 ET
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development...
Chinook Therapeutics to Present at Upcoming Investor Conferences
18. November 2020 16:15 ET
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development...
Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer
10. November 2020 08:15 ET
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development...
Chinook Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
05. November 2020 17:07 ET
|
Chinook Therapeutics, Inc.
Upon closing of the merger with Aduro on October 5th, Chinook had approximately $290 million in cash, cash equivalents and marketable securities to fund advancement of its pipeline of precision...
Chinook Therapeutics Presents Data Across Kidney Disease Pipeline During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined
22. Oktober 2020 11:15 ET
|
Chinook Therapeutics, Inc.
Informational poster presentation on phase 3 ALIGN trial design for atrasentan in IgA nephropathyEncore poster presentation on phase 1 healthy volunteer data for BION-1301 in IgA...
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined
09. Oktober 2020 12:45 ET
|
Chinook Therapeutics, Inc.
Presentations on atrasentan and BION-1301 clinical programs for the treatment of IgA Nephropathy First presentation on CHK-366, a novel oral small molecule lactate dehydrogenase (LDH) inhibitor for...
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
05. Oktober 2020 09:00 ET
|
Chinook Therapeutics, Inc.
Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) --...
Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics
01. Oktober 2020 16:05 ET
|
Aduro Biotech, Inc.
One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company...
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results
03. August 2020 16:05 ET
|
Aduro Biotech, Inc.
BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation...
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy
24. Juni 2020 08:15 ET
|
Aduro Biotech, Inc.
BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...